Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.
You may also be interested in...
Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales
Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales
Fair Remedy Or Illegal Penalty? FDA Disgorgement Authority Questioned
Congress should examine whether FDA has the authority to seek disgorgement and restitution in enforcement actions, Hyman, Phelps & McNamara principal John Fleder said Sept. 22